30 results about "Autosomal recessive inheritance" patented technology

This invention provides primers for in vitro diagnosis of mutation of autosomal recessive nonsyndromic hearing loss gene GJB2. The primers can be used for completely amplifying the coding region and upstream or downstream important splicing sequences of GJB2 gene. This invention also provides a test kit for containing the primers and ApaI restriction endonuclease and their application for in vitro detection of 233-235delC mutation of the complete GJB2 coding region. The test kit can also be used for detecting the mutation sites of the GJB2 coding region through sequencing by the forward primer, and detecting deletion or insertion heterozygous mutation through sequencing by the reverse primer. The test kit is suitable for large-scale screening of autosomal recessive nonsyndromic hearing loss gene GJB2 mutation and genetic counseling.

The present disclosure relates to methods for detecting unique genetic signatures derived from markers such as, for example, mutations, somatic or germ-line, in nucleic acids obtained from biological samples. The sensitivity of the methods provides for detection of mutations associated with a disease, e.g., cancer mutations, or with inherited disease, e.g., an autosomal recessive disease, in a noninvasive manner at ultra-low proportions of sequences carrying mutations to sequences carrying normal, e.g., non-cancer sequences, or a reference sequence, e.g., a human reference genome.

The invention discloses an oculocutaneous albinism type 1 related mutated TYR gene and application thereof to gene diagnosis. By collection of a 4-generation oculocutaneous albinism type 1 family, a transmission manner of 4-generation oculocutaneous albinism type 1 in the family is an autosomal recessive inheritance manner according to judgment; by reading of documents and online databases, possible pathogenic candidate genes are selected, then a propositus and other members in the family are subjected to PCR (polymerase chain reaction) amplification and Sanger sequencing to determine mutant gene loci, and consequently a TYR pathogenic gene (mutant c.107G) which is a novel pathogenic mutation is discovered. Discovery of the novel TYR pathogenic gene mutation locus enriches a pathogenic gene mutation spectrum, and the novel TYR pathogenic gene mutation locus can be used as a prenatal diagnosis screening locus for oculocutaneous albinism type 1 which is a serious recessive hereditary disease to guide prenatal and postnatal care. By providing of the oculocutaneous albinism type 1 related mutated TYR gene, data support is provided for design of prenatal diagnosis chips, and especially,important significance to prenatal gene diagnosis screening of seriously-harmful rare genetic diseases is achieved.

The invention provides a high-throughput sequencing variation risk grouping and screening method. The method comprises the following steps: setting pathogenicity high-risk variation screening conditions, and screening gene data according to the pathogenicity high-risk variation screening conditions; setting pathogenicity high-risk variation screening conditions and medium-risk variation screening conditions with extremely low crowd frequency, and screening the gene data; setting pathogenicity medium-high risk variation screening conditions, and screening the gene data; setting gene variation screening conditions of pathogenicity medium and high risk autosomal dominant heredity, and screening the gene data; setting conditions of pathogenicity medium-high-risk autosomal recessive inheritance and the same gene, and screening the gene data; setting variation screening conditions of high-risk sex-linked inheritance in pathogenicity, and screening the gene data; and setting screening conditions for determining pathogenicity variation or suspicious pathogenicity variation with high risk in pathogenicity, and screening the gene data.

It is intended to provide an agent for regulating axon extension during neuranagenesis by regulating ephrin-Eph receptor signaling mechanisms and to provide a mouse having abnormal ephrin-Eph receptor signaling mechanisms. The present invention relates to a regulator of axon extension, comprising an agent for promoting or suppressing the function of α-chimerin, and to a miffy (mfy) mouse derived from a B6 strain, which displays autosomal recessive inheritance of an abnormal walking trait exhibiting a hopping gait with left-right synchronized movement of limbs and has mutation in an α-chimerin gene.

The invention provides the primary familial cerebral calcification pathogenic gene JAM2 and its application. Specifically, the present invention provides a use of the JAM2 gene, or its protein, or its detection reagent, for preparing a detection reagent or kit, which is used to detect primary familial brain calcification and / or its susceptibility. The present invention identifies JAM2 gene as a new pathogenic gene of autosomal recessive primary familial brain calcification for the first time; and, primary familial brain calcification can be diagnosed by detecting the mutation of JAM2 gene or its protein patients and / or their susceptibility.

The invention provides a high-throughput sequencing variation risk grouping screening method and system, and the method comprises the steps: setting pathogenicity high-risk variation screening conditions, and screening gene data according to the pathogenicity high-risk variation screening conditions; setting pathogenicity high-risk variation screening conditions and medium-risk variation screening conditions with extremely low crowd frequency, and screening gene data; setting pathogenicity medium-high risk variation screening conditions, and screening gene data; setting gene variation screening conditions of pathogenicity medium and high risk autosomal dominant heredity, and screening gene data; setting screening conditions of pathogenicity medium-high-risk autosomal recessive inheritance and the same gene, and screening the gene data; setting variation screening conditions of high-risk sex-linked inheritance in pathogenicity, and screening the gene data; and setting screening conditions for determining pathogenicity variation or suspicious pathogenicity variation with high risk in pathogenicity, and screening the gene data.

The present invention relates to the field of detection technology in medical molecular physiology, it is a kit for detecting autosomal dominant inheritance polycystic kidney disease. According to the structure property of pathogenic gene type A and type B of patient said invention can synthesize correspondent primer, adopt molecular physiological techonlogy and combine it with single-strand conformation polymorphism analysis method or high-pressure liquid-phase chromatography analysis method to make detection, and can directly detect out the mutant site and mutation type of pathogenic gene of the autosomal recessive inheritance polycystic kidney disease for preventing and curing said disease.

The invention provides a genetic risk early-warning method for auxiliary reproduction sperm supplying strategy and a system. According to the method and the system, an autosome recessive genetic disease reproduction genetic risk of a to-be-pregnant women is evaluated and predicted, and a sperm donation volunteer who has relatively high gene pairing degree and low genetic disease risk as a to-be-selected object. Quantification and automation for risk evaluation of a reproduction autosome recessive genetic disease are comprehensively realized. The method and the system have advantages of greatlyreducing manpower cost and time cost, realizing high reasonability, and greatly improving analysis accuracy.

An object of the present invention is to provide a mouse which has the characteristics of early developing visceral fat type obesity and also has concurrent diabetes and hyperlipemia and in which the trait is genetically established and recessively inherited. An ICR-derived mouse strain, Daruma, spontaneously developing obesity, exhibiting autosomal recessive inheritance for the trait of spontaneously developing obesity, and becoming obese only in the homozygous type is provided.

The present invention reveals that the MSH6 mutant gene with g.[12907inCAGC] mutation is a new pathogenic gene of HR, and the sequence of the mutant fragment of the MSH6 mutant gene is shown in SEQ ID NO:4. The diploid homozygous genotype of the MSH6 mutant gene having the sequence shown in SEQ ID NO: 4 can lead to the occurrence of human hypophosphatemic rickets, and has SEQ ID NO: 4 and SEQ ID NO: 1-SEQ ID NO: 3 The diploid heterozygous genotype composed of any MSH6 mutation gene in the sequence shown can also lead to the occurrence of human hypophosphatemic rickets, and all of them are autosomal recessive. On this basis, the present invention provides two mutation detection kits based on PCR capture sequencing and conventional PCR and Sanger sequencing, which are of great significance for HR screening, diagnosis, and fertility guidance, and are especially helpful for Prevent the birth of children with HR at the source. In addition, the discovery of specific mutations in the MSH6 gene is also helpful for the exploration of the pathogenesis of HR and the development of therapeutic drugs and methods.

The invention discloses the use of the compound represented by formula I in preventing, treating or improving hereditary cerebellar ataxia, especially autosomal recessive spinocerebellar ataxia 20 (SCAR20). The compound of the invention can significantly improve the motor ataxia of model mice and slow down the death of Purkinje cells, thereby providing clinical support for the treatment of hereditary cerebellar ataxia, especially SCAR20.

The invention discloses primers and method for detecting PKLR gene mutation of autosomal recessive inherited disease pyruvate kinase deficiency patients. The primers comprise primers for amplifying all exon sequences of the PKLR gene, and the Sanger sequencing technique and sequencing primers are adopted. Mutation of all exons of the PKLR gene in pyruvate kinase deficiency patients can be detected quickly. A detection result is accurate, assistant diagnosis of pyruvate kinase deficiency can be achieved, and reference is provided for early intervention, early treatment and prenatal diagnosis.

The invention relates to an autosomal recessive Kartagener syndrome mutant gene and its application. The advantages of the invention are as follows: the present invention finds the missense of the No. 5 exon of the gene in the family by PCR amplification and sequence determination of the DANAF5 gene of an autosomal recessive Kartagener syndrome family, taking the GRCh37 / h19 genome sequence as a reference. Mutation (T>G) + frameshift mutation in exon 9 (CCA>C) is a compound pathogenic mutation, which is the first report at home and abroad, and is a newly discovered pathogenic mutation in Kartagener syndrome. This mutation can be used in prenatal diagnosis and genetic counseling for Kartagener syndrome to reduce birth defects. Based on this, a reagent for detecting DNAAF5 gene exons 5 and 9 can be used to prepare a reagent for diagnosing Kartagener syndrome, and a diagnostic kit can be developed.

The present invention discloses that the MSH6 mutant gene with g.[12759inTTAAG] mutation is a new pathogenic gene of HR, and the sequence of the mutant fragment of the MSH6 mutant gene is shown in SEQ ID NO:3. The diploid homozygous genotype of the MSH6 mutant gene having the sequence shown in SEQ ID NO: 3 can lead to the occurrence of hypophosphatemic rickets in humans, and has SEQ ID NO: 3 and SEQ ID NO: 1, SEQ ID NO: 2, The diploid heterozygous genotype composed of any MSH6 mutation gene in the sequence shown in SEQ ID NO: 4 can also cause the occurrence of human hypophosphatemic rickets, and all of them are autosomal recessive inheritance. On this basis, the present invention provides two mutation detection kits based on PCR capture sequencing and conventional PCR and Sanger sequencing, which are of great significance for HR screening, diagnosis, and fertility guidance, and are especially helpful for Prevent the birth of children with HR at the source. In addition, the discovery of specific mutations in the MSH6 gene is also helpful for the exploration of the pathogenesis of HR and the development of therapeutic drugs and methods.

The present invention discloses that the MSH6 mutant gene with g.[7957inAA] mutation is a new pathogenic gene of HR, and the sequence of the mutant fragment of the MSH6 mutant gene is shown in SEQ ID NO:2. The diploid homozygous genotype of the MSH6 mutant gene having the sequence shown in SEQ ID NO: 2 can lead to the occurrence of hypophosphatemic rickets in humans, and has SEQ ID NO: 2 and SEQ ID NO: 1, SEQ ID NO: 3, The diploid heterozygous genotype composed of any MSH6 mutation gene in the sequence shown in SEQ ID NO: 4 can also cause the occurrence of human hypophosphatemic rickets, and all of them are autosomal recessive inheritance. On this basis, the present invention provides two mutation detection kits based on PCR capture sequencing and conventional PCR and Sanger sequencing, which are of great significance for HR screening, diagnosis, and fertility guidance, and are especially helpful for Prevent the birth of children with HR at the source. In addition, the discovery of specific mutations in the MSH6 gene is also helpful for the exploration of the pathogenesis of HR and the development of therapeutic drugs and methods.

The present invention discloses that the MSH6 mutant gene with g.[7785-7788delGTGA] mutation is a new pathogenic gene of HR, and the sequence of the mutant fragment of the MSH6 mutant gene is shown in SEQ ID NO:1. The diploid homozygous genotype of the MSH6 mutant gene having the sequence shown in SEQ ID NO: 1 can lead to the occurrence of human hypophosphatemic rickets, and has SEQ ID NO: 1 and SEQ ID NO: 2-SEQ ID NO: 4 The diploid heterozygous genotype composed of any MSH6 mutation gene in the sequence shown can also lead to the occurrence of human hypophosphatemic rickets, and all of them are autosomal recessive. On this basis, the present invention provides two mutation detection kits based on PCR capture sequencing and conventional PCR and Sanger sequencing, which are of great significance for HR screening, diagnosis, and fertility guidance, and are especially helpful for Prevent the birth of children with HR at the source. In addition, the discovery of specific mutations in the MSH6 gene is also helpful for the exploration of the pathogenesis of HR and the development of therapeutic drugs and methods.